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Abstract: Vasomotor symptoms (VMS) associated with menopause can cause signiﬁ  cant 
discomfort and decrease the quality of life for women in the peri-menopausal and post-menopausal 
stages of life. Hormone therapy (HT) is the mainstay of treatment for menopausal symptoms 
and is currently the only therapy proven effective for VMS. Numerous HT options are available 
to treat VMS, including estrogen-only and estrogen-progestogen combination products to meet 
the needs of both hysterectomized and nonhysterectomized women. In addition to selecting an 
appropriate estrogen or estrogen-progestogen combination, consideration should be given to 
the route of administration to best suit the needs of the patient. Delivery systems for hormone 
therapy include oral tablets, transdermal patches, transdermal topical (nonpatch) products, and 
intravaginal preparations. Oral is currently the most commonly utilized route of administration 
in the United States. However, evidence suggests that oral delivery may lead to some undesirable 
physiologic effects caused by signiﬁ  cant gut and hepatic metabolism. Transdermal drug delivery 
may mitigate some of these effects by avoiding gut and hepatic ﬁ  rst-pass metabolism. Advantages 
of transdermal delivery include the ability to administer unmetabolized estradiol directly to the 
blood stream, administration of lower doses compared to oral products, and minimal stimulation 
of hepatic protein production. Several estradiol transdermal delivery technologies are available, 
including various types of patches, topical gels, and a transdermal spray.
Keywords: estradiol, hormone therapy, menopause, transdermal drug delivery, vasomotor 
symptoms
Introduction
Menopause is a biological process whereby ovarian function and production of estra-
diol decrease, ultimately leading to depletion of ovarian follicles and permanent ces-
sation of menses (Blake 2006). The menopausal transition can occur naturally over a 
period of several years or spontaneously as a result of surgical removal of the ovaries, 
chemotherapy, or radiation therapy. Spontaneous natural menopause is identiﬁ  ed 
retrospectively after 12 months of amenorrhea, and reﬂ  ects a near-complete cessation 
of ovarian hormone secretion (Soules et al 2001).
As estradiol levels decline during the peri-menopausal and post-menopausal periods, 
many women experience vasomotor symptoms, breast tenderness, insomnia, migraines, 
and/or premenstrual dysphoria (Deecher 2005). Vasomotor symptoms (VMS) are the 
most commonly experienced effects of the menopausal transition and include both 
hot ﬂ  ashes and night sweats. Long-term estrogen depletion can increase the risk of 
cardiovascular disease and osteoporosis as well as cause vaginal and vulvar atrophy.
Prevalence
Vasomotor symptoms affect an estimated 60% to 80% of post-menopausal women, 
but may be experienced by up to 90% of women during the peri-menopausal stage Drug Design, Development and Therapy 2008:2 194
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(Rapkin 2007). VMS generally subside within two to ﬁ  ve 
years after menopause; however, up to 30% of women report 
VMS into their sixties and almost 10% report VMS into their 
seventies. Moderate to severe intensity VMS are reported by 
40% to 60% of women reporting VMS, and up to 20% report 
nearly intolerable symptoms (Bachmann 2005).
Treatment options
For the treatment of mild VMS, lifestyle changes, either alone 
or in conjunction with nonprescription remedies, are gener-
ally recognized as ﬁ  rst-line treatment options (NAMS 2007). 
Lifestyle modiﬁ  cations include maintaining air temperature 
as cool as possible to help keep the core body temperature 
cool and behavioral changes such as exercising regularly, 
maintaining a healthy body weight, avoiding hot drinks and 
foods that may trigger hot ﬂ  ashes, and using a variety of 
relaxation techniques.
Systemic hormone therapy (HT) is the current standard 
of care for treatment of moderate-to-severe VMS (NAMS 
2007) and is the only treatment option that has consistently 
demonstrated signiﬁ  cant reductions in VMS severity and fre-
quency (Fugate and Church 2004; Bachmann 2005; Deecher 
2005; Nachtigall et al 2006). In addition, prescription HT is 
the only treatment currently approved by the United States 
Food and Drug Administration (FDA) for VMS relief 
(Bachmann 2005). In the US, hormone therapy is avail-
able in oral tablets, transdermal patches, a newly approved 
transdermal spray, transdermal topical gels and intravaginal 
preparations (Ansbacher 2001). Systemic therapy with oral 
and transdermal therapy may be used to treat VMS, vaginal 
atrophy, and prevention of osteoporosis, although approved 
indications vary among products. Vaginal dosage forms are 
generally utilized for local treatment of vulvar and vaginal 
atrophy; however, one vaginal ring is indicated to treat VMS 
(Speroff and the United States VR Investigator Group 2003). 
Estrogenic compounds approved for HT in the US include 
estradiol, conjugated equine estrogens (CEE), conjugated 
estrogens (CE), ethinyl estradiol (EE), and estropipate 
(Minkin 2004).
Alternative treatment options
Nonprescription remedies such as dietary isoflavones, 
black cohosh, and vitamin E have been suggested as pos-
sible alternatives to HT (Fugate and Church 2004). When 
studied in randomized, placebo-controlled studies, these 
remedies have not demonstrated a clinically relevant reduc-
tion in VMS (Newton et al 2006). However, a recent study 
found signiﬁ  cant reductions in severity and frequency of hot 
ﬂ  ashes with a soy isoﬂ  avone extract compared to placebo 
in post-menopausal women experiencing ﬁ  ve or more hot 
ﬂ  ashes per day at baseline after 10 months of treatment 
(Nahas et al 2007). The soy supplement employed in this 
trial was highly puriﬁ  ed and was tested to ensure that the 
composition and potency were standardized among all par-
ticipants. The authors speculate that the lack of beneﬁ  t noted 
in other trials of soy products may have been affected by the 
purity, composition, and lack of standardized manufacturing 
processes of soy isoﬂ  avone extracts.
Off-label use of nonhormonal prescription alternatives 
including selective serotonin receptor inhibitors (SSRIs), 
gabapentin, clonidine, or venlafaxine may also be considered 
when lifestyle changes in conjunction with nonprescription 
therapies do not provide adequate relief or when contraindica-
tions to HT are present (Fugate and Church 2004; Bachmann 
2005; Deecher 2005; Nachtigall et al 2006).
Combination HT
Unopposed estrogen therapy (ET) in nonhysterectomized 
post-menopausal women has been associated with an 
increased risk of endometrial hyperplasia, which may be 
a precursor to the development of endometrial cancer. The 
duration of unopposed ET is linked to the risk of endome-
trial cancer. Administration of unopposed ET for 1–2 years 
increases the risk approximately 2.4-fold (NAMS 2003) 
whereas administration for 10 years increases the risk 8- to 
10-fold (Grady et al 1995). Even after discontinuation of ET, 
the risk of endometrial cancer appears to remain elevated for 
at least 5 years (NAMS 2003). Adding a continuous or cyclic 
progestogen to the estrogen regimen provides endometrial 
protection, signiﬁ  cantly reducing the risk of endometrial 
hyperplasia and cancer (NAMS 2007; Doherty et al 2007). 
Progestogens are not required or recommended for hyster-
ectomized women (NAMS 2007).
Randomized controlled trials of HT
The Heart and Estrogen/progestin Replacement Study II 
(HERS II) was an open-label continuation of the HERS study, 
designed to evaluate the cardiovascular effects of 0.625 mg 
CE plus 2.5 mg medroxyprogesterone acetate (MPA) com-
pared to placebo in postmenopausal women with preexisting 
cardiovascular disease (CVD) (Grady et al 2002). While no 
differences in cardiovascular events were noted between the 
two treatment groups over the 4.1 years of follow-up, post-
hoc analysis of the data found a trend toward more events 
in the ﬁ  rst year of treatment, but fewer in years 3 through 5 
(Hulley et al 1998). HERS-II was designed to determine if Drug Design, Development and Therapy 2008:2 195
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this reduction in cardiovascular events would be sustained 
over a longer duration of therapy (Grady et al 2002). The 
planned follow-up in HERS II was an additional 4 years; 
however, the trial was stopped after 2.7 years (thus repre-
senting a total of 6.8 years of enrollment), due to a lack of 
protective beneﬁ  t for HT. No differences were noted between 
HT and placebo relative to cardiovascular events or death 
due to CVD, but women receiving HT had a signiﬁ  cantly 
higher rate of nonfatal ventricular arrhythmia compared to 
those receiving placebo (p = 0.04). In addition, there was 
no trend toward reduced risk of cardiovascular events with 
longer duration of HT (p = 0.18).
Women’s Health Initiative (WHI)
The release of the ﬁ  rst WHI report in July 2002 occurred 
within two weeks of publication of HERS II. Like HERS/
HERS II, WHI was designed to determine whether HT had 
a cardioprotective effect; unlike HERS/HERS II, which 
enrolled women with pre-existing cardiovascular disease, 
WHI enrolled healthy women (Rossouw et al 2002). Two 
different HT regimens were studied: 0.625 mg CEE + 2.5 mg 
medroxyprogesterone (MPA) per day in nonhysterectomized 
women; and 0.625 mg CEE in hysterectomized women (both 
compared to matching placebo).
The estrogen-progestin WHI study was stopped early due 
to increased risk of breast cancer, which had been identiﬁ  ed 
at baseline as a primary adverse outcome to be monitored 
(HR 1.26, 95% CI 1.00–1.59). Media coverage depicting 
this 26% increased risk of breast cancer with estrogen-
progestin therapy caused confusion among many patients as 
well as their healthcare providers, and in many cases made 
the risk of breast cancer with this regimen appear much 
greater than the data revealed. For this reason, many experts 
recommend discussing the risk of breast cancer in terms of 
absolute risk as compared to relative risk. For example, there 
were 38 cases of breast cancer among estrogen-progestin 
users per 10,000 patient years (with 30 cases of breast cancer 
among placebo users per 10,000 patient years).
Unlike previous observational studies (Henderson et al 
1988; Humphrey et al 2002; Stampfer et al 1991; Grodstein 
et al 1996), the WHI found no cardiovascular protective 
beneﬁ  t of the estrogen-progestin combination; in fact, the 
risk of CVD was slightly increased in women receiving 
combination estrogen-progestin therapy (EPT) (Rossouw 
et al 2002). Strokes and venous thromboembolisms (VTEs) 
were also increased among the combination HT users, 
which was offset by a reduction in colorectal cancer cases 
and fractures among combination HT users. No difference 
was seen in overall mortality between hormone therapy and 
placebo users.
Published two years later in 2004 was the estrogen-
only arm of the WHI. Among estrogen users, there was a 
signiﬁ  cantly higher risk of stroke compared to placebo; again, 
this was offset by a lower rate of hip fractures compared 
to placebo users. No signiﬁ  cant differences were noted in 
other clinical outcomes, although there was a trend toward 
reduced cases of breast cancer among the estrogen users 
relative to placebo.
The type of women enrolled in WHI has generated 
criticism as being less than ideal to study primarily due 
to their age (average of 63.3 years at enrollment) and 
discouragement of enrolling women experiencing hot 
ﬂ  ashes at baseline (due to apprehension that women in the 
placebo group would drop out). To determine whether age 
at which hormone therapy is commenced may impact the 
cardiovascular effects, a combined analysis of the WHI trials 
was recently completed (Rossouw et al 2007). Researchers 
performed subgroup analysis on women who were 1) less 
than 10 years; 2) 10–19 years; and 3) 20 or more years past 
the age of menopause at initiation of HT. For women less 
than 10 years post-menopausal at study entry, the hazard 
ratio (HR) of CVD was 0.76 (95% CI, 0.5–1.16). The HR 
for women 10–19 years post-menopausal at study entry 
was 1.1 (95% CI, 0.84–1.45) whereas it was 1.28 (95% 
CI, 1.03–1.58) for women 20 or more years post-menopausal. 
Trend analysis revealed a decreased risk of CVD if HT was 
initiated within 10 years of menopause (p = 0.02). However, 
this trend did not reach the predeﬁ  ned level of statistical 
signiﬁ  cance, which was 0.01. While p-values of less than 0.05 
are often accepted as the benchmark for statistical signiﬁ  -
cance, the authors selected the lower level for this analysis to 
account for the post hoc nature of this analysis. Nonetheless, 
these ﬁ  ndings, coupled with the realization that the average 
age at which women were enrolled increased the likelihood of 
subclinical cardiovascular disease, has generated signiﬁ  cant 
interest and increased the level of comfort with initiating 
hormone therapy in younger, symptomatic women.
The WHI was the largest controlled clinical trial to date 
evaluating HT in post-menopausal women; however, this study 
only evaluated one HT regimen for hysterectomized women 
(CEE 0.625 mg orally) and one for nonhysterectomized women 
(CEE 0.625 mg + MPA 2.5 mg). Thus, some researchers 
caution that the results found in these studies may not apply to 
different doses of the same products, other estrogen or progestin 
compounds, or to products administered by the transdermal 
or vaginal route (Rossouw et al 2002; Anderson et al 2004). Drug Design, Development and Therapy 2008:2 196
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Nonetheless, the US FDA requires a black box warning on all 
post-menopausal HT products regarding the potential risks 
identiﬁ  ed by the WHI (Stephenson 2003). In addition, as a 
result of HERS, HERS II, and the WHI, HT is no longer rec-
ommended solely for the prevention of cardiovascular disease 
in post-menopausal women (ACOG 2004; Nelson et al 2005; 
NAMS 2007).
Post-WHI recommendations to utilize the lowest dose 
for the lowest duration possible have generated interest 
and the introduction of new low-dose and ultra-low-dose 
HT products (Stephenson 2003; ACOG 2004; NAMS 
2007). Increasing attention is also being paid to the route 
of administration. Oral products, particularly CE alone or 
in combination with a progestin (such as those studied in 
WHI), experienced a large decline in volume following 
the publication of WHI. (Hersh et al 2004). In recent years, 
emerging evidence is accumulating regarding the differences 
between the transdermal and oral route of administration for 
pharmacokinetic parameters, lipid effects, impact on clotting 
proteins, and various other processes owing to the avoidance 
of ﬁ  rst-pass metabolism.
Oral vs transdermal: 
Pharmacokinetic differences
While both oral and transdermal HT have been proven effec-
tive for relief of menopausal symptoms, several differences 
exist between these routes that may inﬂ  uence safety and 
patient acceptance of the regimen. Oral administration of 
estrogen is associated with extensive gut and ﬁ  rst-pass liver 
metabolism as well as signiﬁ  cant hepatic stimulation (Balfour 
and Heel 1990). To overcome these metabolism processes, 
oral estrogens must be administered in relatively high doses 
to provide blood levels adequate to reduce menopausal 
symptoms. Extensive metabolism of oral estrogens results 
in conversion of a large portion of the dose to estrone and its 
conjugates, which have less estrogenic activity than estradiol. 
Signiﬁ  cant metabolic conversion of oral estrogens to estrone 
results in a higher ratio of estrone to estradiol in the blood 
stream, which is opposite of the physiological levels in pre-
menopausal women (Gleason et al 2005). In addition, some 
metabolites of conjugated estrogens formed during ﬁ  rst-pass 
metabolism appear to have antiestrogenic or unrecognized 
pharmacologic activity in the human body (Campagnoli 
et al 1999). Conversely, transdermal dosage forms deliver 
estradiol directly to the systemic circulation through the skin, 
bypassing gut and ﬁ  rst-pass hepatic metabolism (Balfour 
and Heel 1990). Avoidance of gut and liver metabolism via 
transdermal administration helps maintain an estradiol to 
estrone ratio similar to that found in premenopausal women 
(Chetkowski et al 1986). However, the clinical relevance of 
the estradiol-to-estrone ratio is currently unknown.
Signiﬁ  cant variations in the metabolism of oral estrogens 
results in wide ﬂ  uctuations in estrogen blood levels through-
out the day, potentially resulting in inconsistent control of 
VMS (Scott et al 1991; Minkin 2004). Transdermal admin-
istration provides more consistent blood levels by avoiding 
the peaks and troughs inherent to oral estrogens.
Lipid effects
Prior to menopause, endogenous estrogen plays a vital role 
in lipid metabolism and maintenance of healthy lipid levels. 
During the peri-menopausal and post-menopausal periods, 
estrogen depravation contributes to increasing levels of 
low-density lipoprotein (LDL) cholesterol and triglycerides 
(TGs) and decreasing levels of high-density lipoprotein 
(HDL) cholesterol (Menon et al 2006). Exogenous estrogen 
administration in peri-menopausal and post-menopausal 
women has been shown to improve lipid proﬁ  les (Table 1). 
However, differences exist between the lipid effects of oral 
and transdermal estrogens.
Oral and transdermal estrogens have both been shown to 
increase HDL and decrease LDL and total cholesterol (Sacks 
and Walsh 1994; Hanggi et al 1997; Shulman et al 2003). 
However, signiﬁ  cant hepatic stimulation with oral estrogens 
increases production of TGs whereas transdermal estrogens 
have a neutral effect on TG levels. Thus, the route of 
Table 1 Differential effects of oral and transdermal estrogens on 
lipids and coagulation factors
Oral estrogens Transdermal 
estrogens
Total cholesterol ↓↓
HDL-C ↑↑
LDL-C ↓↓
TG ↑ Neutral or ↓
APC activity ↓ Neutral
CRP ↑ Neutral
AT III ↓ Neutral
Fibrinogen ↓↓
Factor VII activity Neutral ↓
von Willebrand factor ↑ Neutral or ↓
Prothrombin fragments 
1 and 2
↑ Neutral or ↓
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; TGs, triglycerides; APC, activated protein C; CRP, C-reactive 
protein; AT III, Antithrombin III.Drug Design, Development and Therapy 2008:2 197
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estrogen administration should be considered in women 
with hyperlipidemia as elevated TGs are recognized as an 
independent risk factor for coronary heart disease (CHD) and 
increased mortality (Fletcher et al 2005). Additionally, the 
American Association of Clinical Endocrinologists (AACE) 
recommends considering transdermal hormone therapy 
instead of oral therapy for women with elevated TGs or 
hypertension (AACE 2006).
With respect to LDL, the atherogenicity of LDL may 
also be inﬂ  uenced by the route of estrogen administration 
(Wakatsuki et al 2002). TG levels affect the size of LDL 
particles; higher TG levels contribute to the production of 
smaller, TG-rich LDL particles (McNamara et al 1992) that 
are more susceptible to oxidation (Wakatsuki et al 2002). 
Increased circulating levels of oxidized LDL particles are 
believed to be associated with atherosclerotic plaque instabil-
ity and an increased risk of cardiovascular events (Ehara et al 
2001). Conversely, by avoiding signiﬁ  cant hepatic exposure, 
transdermal estrogens do not cause increased production of 
TGs. Thus, despite an overall lowering of total cholesterol 
and LDL with oral estrogens, increasing production of TGs 
may reduce some of the lipid beneﬁ  ts inherent to endogenous 
estrogens (Wakatsuki et al 2002).
The quality of cholesterol molecules can be further 
affected by the route of estrogen administration. Serum 
amyloid A (SAA) is an acute-phase protein produced by 
the liver that is associated with atherosclerosis and vascular 
inﬂ  ammation (Liang et al 1996). Oral estrogens increase 
production of SAA, which when incorporated into HDL 
particles, can negatively affect the antiatherogenic, antioxi-
dant, and antiinﬂ  ammatory actions of HDL (Kisilevsky and 
Subrahmanyan 1992). Conversely, transdermal estrogens do 
not effect SAA production and thus do not appear to mitigate 
the positive effects of HDL (Abbas et al 2004).
C-reactive protein
C-reactive protein (CRP) is an acute-phase protein that 
has been recognized as a marker for vascular inﬂ  amma-
tion and atherosclerosis (Pasceri et al 2000). High CRP 
levels are considered an important predictor of the risk 
for ﬁ  rst myocardial infarction and stroke in otherwise 
healthy people, independent of other CVD risk factors 
(Ridker et al 2000; Pradhan et al 2002). Due to the utility 
of CRP in predicting future cardiovascular disease, the 
Centers for Disease Control (CDC) and the American 
Heart Association (AHA) recommend CRP testing and 
lipid screening in healthy people with an intermediate 
risk of CVD (Smith et al 2004).
Oral estrogens, via hepatic stimulation, increase 
production of CRP by the liver (Van Baal et al 1999; Skouby 
et al 2002). In addition, increases in CRP induced by oral 
estrogens may be accompanied by a decrease in insulin-
like growth factor 1 (IGF-1), an antiinﬂ  ammatory protein 
that helps to regulate the inflammatory effects of CRP 
(Weissberger et al 1991). Conversely, transdermal estrogen 
does not affect CRP production and may even decrease 
levels to some degree (Sattar et al 1999; Decensi et al 2002; 
Strandberg et al 2003; Lacut et al 2003; Vongpatanasin et al 
2003). As such, transdermal estrogens may be preferred 
over oral estrogens in women with cardiovascular disease 
(CVD) or women at high risk for developing CVD due to 
the neutral CRP effects of transdermal delivery (Strandberg 
et al 2003).
Activated protein C (APC)
Activated protein C (APC) is a potent thrombin inhibitor that 
has been recognized as a marker for cardiovascular disease, 
with reduced activity of APC contributing to an increased risk 
of cardiovascular events (deVisser et al 1999; Rodeghiero 
and Tosetto 1999). Oral estrogens appear to decrease the 
thrombin-inhibiting activity of APC and may contribute to 
development of APC resistance (Oger 2003). Conversely, 
transdermal HT administration is associated with minimal 
effects on APC activity and has not been linked to develop-
ment of APC resistance (Oger et al 2003; Post et al 2003).
Venous thromboembolism (VTE)
Exogenous estrogen administration has been shown to affect 
the levels and activity of certain blood coagulation factors. 
Antithrombin III (AT III) is a potent coagulation inhibitor that 
may increase the risk of thrombosis if not present in adequate 
levels (Bonduki et al 1998). Oral estrogens decrease AT III 
levels whereas transdermal estrogens appear to have no effect 
on antithrombin III levels. Numerous other studies have 
found that compared to oral estrogens, transdermal estrogens 
have minimal negative impact on other coagulation factors, 
including ﬁ  brinogen, factor VII, von Willebrand factor, and 
prothrombin fragments 1 + 2 (Scarabin et al 1997; Oger et al 
2003; Schmidt et al 2006; Menon et al 2006).
An increased risk of venous thromboembolism (VTE) 
with oral hormone therapy has been shown in both obser-
vational and randomized trials (Scarabin et al 2003; Gomes 
and Deitcher 2004; Canonico et al 2007, 2008). While the 
VTE risk associated with transdermal estrogens has not been 
as extensively studied, available evidence suggests that this 
route may have less propensity toward VTE compared to Drug Design, Development and Therapy 2008:2 198
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oral administration. This is supported by differences in the 
production and activity of several clotting factors between 
these two routes of administration as well as results from a 
case-control study (Canonico et al 2007).
Recently, VTE risk between oral and transdermal HT 
was compared in the Estrogen and Thromboembolism Risk 
(ESTHER) study, which enrolled 881 post-menopausal 
women (Canonico et al 2007). This case-control study 
found that the odds ratio of VTE in women using oral 
HT was 4.2 compared to 0.9 for women receiving trans-
dermal HT. Adjustments for confounding factors such 
as obesity, family history of VTE, history of varicose 
veins, education, age at onset of menopause, hysterec-
tomy, and cigarette smoking did not significantly effect 
these results.
In a previous evaluation of the ESTHER study data, 
Straczek and colleagues (2005) evaluated the VTE risk of 
oral and transdermal HT in women with a Factor V Leiden or 
other prothrombotic mutations. While oral HT increased the 
risk of VTE 25-fold in women with a prothombotic mutation, 
transdermal HT had no impact on VTE risk above and beyond 
the risk already associated with the mutation (Straczek et al 
2005) (Figure 1). Randomized controlled trials are needed 
to conﬁ  rm the long-term safety of transdermal estrogen, 
particularly in women with prothrombotic mutations or other 
risk factors for VTE.
Sex hormone-binding globulin
Sex hormone-binding globulin (SHBG) is partially 
responsible for controlling the amount of free testoster-
one in the blood stream, thereby aiding in the regulation 
of the androgenic effects of testosterone (Minkin 2004). 
In excess, SHBG reduces free testosterone levels and thus 
may decrease libido. Liver metabolism and continued 
hepatic exposure to estrogen and its metabolites following 
oral estrogen administration increases production of 
SHBG (Campagnoli et al 1993). Conversely, transder-
mal estrogen has little effect on SHBG production or 
circulating free testosterone. Therefore, women with low 
testosterone or those experiencing sexual dysfunction 
may beneﬁ  t from transdermal estrogen rather than oral 
estrogen (Campagnoli et al 1993; Vehkavaara et al 2000; 
Samisoe 2001).
Compliance
Maintaining compliance with HT regimens is an ongoing 
challenge (Hope and Rees 1995; Kayser et al 2001). One 
survey of a managed care database found that nearly 75% 
of women discontinued HT within 2 years of initiation, no 
matter the product or dosage form used (Kayser et al 2001). 
The primary reasons for discontinuation are side effects, 
including menstrual bleeding, breast tenderness, weight 
gain, and a fear of cancer (Samsioe 2004). Vaginal bleed-
ing and spotting appear to be lessened by using low-dose 
or ultra-low-dose products (Mattsson et al 1999; Sturdee 
et al 2008). By avoiding gut metabolism, gastrointestinal 
side effects such as nausea, vomiting, and abdominal pain 
are also less common with transdermal products (Cano 
1994; Hirvonen 1997; Archer 2003; Simon 2006). In addi-
tion, by allowing use of lower hormone doses, transdermal 
HT is generally associated with fewer systemic adverse 
effects, such as vaginal bleeding and breast tenderness 
(Hivonen 1997).
Transdermal delivery technology
The clinical beneﬁ  ts of transdermal estradiol delivery are 
applicable to all transdermal HT products. Several transder-
mal delivery technologies are utilized for HT products to treat 
VMS, including patches, gels, an intravaginal ring (Simon 
and Ravnikar 2007) and a transdermal spray. Transdermal 
delivery bypasses ﬁ  rst-pass hepatic metabolism, thereby 
allowing administration of lower doses and provides more 
stable blood levels than oral HT. While equivalent doses of 
estradiol likely provide equivalent efﬁ  cacy no matter the 
delivery system, differences in the application requirements 
and product formulations may inﬂ  uence patient acceptance 
of and compliance with these delivery systems.
The ﬁ  rst technology used for transdermal delivery of 
HT was the reservoir patch, which is constructed with a 
drug reservoir, a backing layer, and an alcohol-containing 
membrane that controls the rate of drug release into the 
blood stream (Nachtigall 1995; Musel and Warshaw 2006). 
Reservoir patches were designed to provide more stable 
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estrogen blood levels than oral estrogen, but they have been 
associated with local irritation rates of up to 46% (Samsioe 
2004). Adhesive composition or the alcohol solvent system 
is generally thought to be responsible for cutaneous reactions 
caused by reservoir patches (Musel and Warshaw 2006).
Matrix patches were the next advance in the area of 
transdermal patch technology. This patch design includes a 
solution or suspension of active ingredient within a polymer 
or textile pad that is held in direct contact with the skin. 
Adhesive is applied only to the perimeter of the patch itself. 
This design provides a more consistent drug delivery rate than 
reservoir patches. In addition, matrix patches are generally 
associated with fewer skin reactions, primarily due to the lack 
of alcohol and the ability to allow better air circulation to 
the skin underneath (Simon 2004). The most recent advance 
in matrix patches was the incorporation of dot matrix tech-
nology, which combines the drug and adhesive in a single 
layer. Dot matrix patches are smaller and thinner than other 
patches and provide the most consistent drug delivery among 
transdermal patches with the lowest rates of local irritation 
among transdermal patches (Reginster et al 2000).
Transdermal patches were designed to improve compli-
ance over oral therapy by providing once- or twice-weekly 
dosing with a relatively easy to use dosage form. However, 
some patches, particularly reservoir patches, are associ-
ated with relatively high rates of application site reactions 
including erythema, pruritis, and edema (Samsioe 2004). 
Additionally, up to 10% of patches may fall off prematurely, 
potentially leading to a disruption in the dosing cycle 
(Erianne and Winter 1997). Patches may also become dirty 
during the course of wear and leave behind a sticky adhesive 
residue. Moreover, some women may object to their visual 
appearance. The release rate of some patches may also be 
affected by temperature; thus, they should not be applied in 
a location where they would be exposed to direct sunlight 
(Estraderm® PI 2005).
The next advance was the development of estradiol 
topical gels, which were designed to overcome the local 
irritation caused by transdermal patches (Archer and 
EstroGel Study Group 2003; Simon et al 2007). In addi-
tion to improved tolerability, dose titration is possible with 
some gel products (Divigel® PI 2007; Simon et al 2007). 
These products utilize an alcohol base to solvate the skin 
and allow the estradiol to diffuse through the skin layers. To 
ensure adequate absorption, gels often require application to 
the entire arm and necessitate the patient to directly contact 
the active drug substance, potentially increasing the risk of 
transfer to another person. In addition, gels must be allowed 
to dry for several minutes before dressing to prevent transfer 
of estradiol or the gel itself to clothing. Contact of others 
with the application site should be avoided for at least 1 hour 
(Divigel® PI 2007) to 2 hours (Elestrin® PI 2007) to avoid 
transfer of the active drug. To prevent affecting the absorption 
of estradiol, the gel application site should be kept dry as long 
as possible after application; therefore, washing or bathing 
should occur before application of a gel product.
The latest development in percutaneous drug delivery 
is an estradiol transdermal spray which recently received 
FDA approval for treatment of moderate-to-severe VMS 
(Evamist™, Ther-Rx Corporation, St. Louis, MO, USA). 
The transdermal spray technology incorporates estradiol, 
octisalate, and alcohol into a unique and patented drug deliv-
ery system. Upon localized application to the inner forearm, 
alcohol solvates the stratum corneum and allows the estradiol 
and octisalate to penetrate the top layer of skin. The alcohol 
then quickly evaporates, leaving a depot of octisalate and 
estradiol. Octisalate facilitates the slow descent of estradiol 
through the epidermis into the dermis, where it is absorbed 
into the systemic circulation through the capillary beds. Simi-
lar to topical gels, this technology provides 24-hour sustained 
delivery of estradiol while maintaining low blood levels with 
once-daily dosing (Figure 2). Additionally, application site 
reactions with estradiol transdermal spray were reported in 
1.3% of patients in a clinical study (Buster et al 2008).
Estradiol transdermal spray provides the advantages 
of nonoral estradiol delivery while addressing some of the 
potential drawbacks to topical gels. The spray dries com-
pletely and invisibly in a median of 67 seconds and leaves 
no residue on the skin, allowing women to dress within 
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Figure 2. Mean (±SD) serum estradiol concentrations on day 14 following topical appli-
cation for 14 days of one, two, or three sprays of Evamist (unadjusted for baseline).
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2 minutes of application (Buster et al 2008). In addition, 
washing of the application site is permissible 30 minutes 
after dosing. The applicator device also eliminates the need 
for direct contact with the active drug substance, minimizing 
the risk of transfer to clothing or other people compared to 
topical gels. To further reduce the risk of transfer to other 
people, 30 minutes should elapse before allowing contact 
with the application area.
Estradiol transdermal spray is packaged in a metered-dose 
pump encased in a plastic housing with a conical bell open-
ing. When pressed against the inner forearm, the applicator 
device controls the distance, angle, and area of application, 
thereby reducing the risk of inappropriate application or vari-
ability in application technique. Each metered-dose pump 
is designed to deliver 56 sprays of precisely 90 mcL, which 
contains 1.53 mg of estradiol. As with many transdermal 
estrogen therapies, administration of higher doses of estradiol 
to the surface of the skin does not proportionally increase 
the amount of estradiol absorbed into the systemic circula-
tion. Thus, the amount of estradiol delivered to the systemic 
circulation is approximately 0.021-, 0.029-, and 0.04-mg per 
day for the 1-, 2-, and 3-spray doses, respectively (Buster 
et al 2008). Signiﬁ  cant reductions in frequency and severity 
of moderate-to-severe hot ﬂ  ashes have been demonstrated 
at all three dosage levels compared to placebo.
The indicated starting dose is 1 spray per day with the 
option of titrating upward depending upon individual patient 
response. The ability to titrate the dose allows women to uti-
lize the lowest effective dose, consistent with current recom-
mendations by FDA, American College of Obstetricians and 
Gynecologists (ACOG) and The North American Menopause 
Society (NAMS). In addition, as estrogen-related side effects 
appear to generally be dose-related, administration of lower 
doses may thus reduce the risk of adverse effects such as 
breakthrough bleeding and breast tenderness (Lobo 2004).
Conclusion
Of the various HT options, transdermal delivery is emerging 
as an increasingly attractive option given the potential for 
an improved safety proﬁ  le. While further study is needed, 
ongoing studies such as the Kronos Early Estrogen Preven-
tion Study (KEEPS) should provide valuable insight regard-
ing the relative safety of transdermal HT compared to oral 
(Harman et al 2005). Several estradiol transdermal delivery 
technologies are available for the treatment of moderate-
to-severe VMS in postmenopausal women. Due to their 
lack of ﬁ  rst-pass hepatic metabolism, transdermal products 
achieve clinical beneﬁ  ts while minimizing patient exposure 
to estrogens, which is consistent with the most recent clinical 
guidelines. The latest development in percutaneous drug 
delivery, estradiol transdermal spray, offers both the female 
patient and the clinician a unique option among the hormone 
therapy armamentarium for the individualized treatment of 
VMS due to menopause.
Disclosure
The authors are employed by KV Pharmaceutical, the parent 
company of Ther-Rx Corporation, which markets Evamist 
(estradiol transdermal spray).
References
Abbas A, Fadel PJ, Want Z, et al. 2004. Contrasting effects of oral versus 
transdermal estrogen on serum amyloid A (SAA) and high-density 
lipoprotein-SAA in post-menopausal women. Arterioscler Thromb 
Vasc Biol, 24:e164–67.
ACOG Task Force on Hormone Therapy. 2004. Hormone therapy. Obstet 
Gynecol, 104(suppl):1s–131s.
[AACE] American Association of Clinical Endocrinologists. 2006. AACE 
medical guidelines for clinical practice for management of menopause. 
Endocrinol Pract, 12:315–37.
Anderson GL, Limacher M, Assaf AR, et al; Women’s Health Initiative 
Steering Committee. 2004. Effects of conjugated equine estrogen in 
post-menopausal women with hysterectomy: the Women’s Health 
Initiative randomized controlled trial. JAMA, 291:1701–12.
Ansbacher R. 2001. The pharmacokinetics and efﬁ  cacy of different estrogens 
are not equivalent. Am J Obstet Gynecol,184:255–63.
Archer DF, EstroGel Study Group. 2003. Percutaneous 17-beta-estradiol gel 
for the treatment of vasomotor symptoms in post-menopausal women. 
Menopause, 10:516–21.
Archer DF. 2003. Percutaneous 17-beta estradiol gel for the treatment 
of vasomotor symptoms in post-menopausal women. Menopause, 
10:516–21.
Bachmann GA. 2005. Menopausal vasomotor symptoms: a review of 
causes, effects, and evidence-based treatment options. J Reprod Med, 
50:155–65.
Balfour JA, Heel RC. 1990. Transdermal estradiol: a review of its pharma-
codynamic and pharmacokinetic properties, and therapeutic efﬁ  cacy in 
the treatment of menopausal complaints. Drugs, 40:561–82.
Blake J. 2006. Menopause: evidence-based practice. Best Pract Res Clin 
Obstet Gynaecol, 20:799–839.
Bonduki CE, Lourenco DM, Baracat E, et al. 1998. Effect of estrogen-
progestin hormone replacement therapy on plasma antithrombin III of 
post-menopausal women. Acta Obstet Gynecol Scand, 77:330–33.
Buster JE, Koltun WD, Pascual MLG, et al. 2008. Low-dose estradiol spray 
to treat vasomotor symptoms. Obstet Gynecol, 111:1343–51.
Campagnoli C, Ambroggio S, Biglia N, Sismondi P. 1999. Conjugated estro-
gens and breast cancer risk. Gynecol Endocrinol, 13 (Suppl 6):13–9.
Campagnoli C, Biglia N, Altare F, et al. 1993. Differential effects of oral 
conjugated estrogens and transdermal estradiol on insulin-like growth 
factor 1, growth hormone and sex hormone binding globulin serum 
levels. Gynecol Endocrinol, 7:251–58.
Cano A. 1994. Compliance to hormone replacement therapy in menopausal 
women controlled in a third level academic centre. Maturitas, 20:91–9.
Canonico M, PluBureau G, Lowe GDO, et al. 2008. Hormone replacement 
therapy and the risk of venous thromboembolism in postmenopausal 
women: systematic review and meta-analysis. BMJ, 336:1227–31.
Canonico M, Oger E, Plu-Bureau G, et al. 2007. Hormone therapy and 
venous thromboembolism among post-menopausal women. Impact of 
the route of estrogen administration and progestogens: the ESTHER 
Study. Circulation, 115:840–5.Drug Design, Development and Therapy 2008:2 201
Transdermal hormone therapy
Chetkowski RJ, Meldrum DR, Dteingold KA, et al. 1986. Biologic effects 
of transdermal estradiol. N Engl J Med, 314:1615–20.
Decensi, A, Omodei U, Chris Robertson C, et al. 2002. Effect of transdermal 
estradiol and oral conjugated estrogens on C-reactive protein in retinoid-
placebo trial in healthy women. Circulation, 106:1224–8.
de Visser MCH, Rosendaal FR, Bertina RM. 1999. A reduced sensitivity 
for activated protein C in the absence of factor V Leiden increases the 
risk of venous thrombosis. Blood, 93:1271–276.
Divigel® PI. 2007. Divigel® prescribing information. Minneapolis, Min-
nesota, USA: Upsher Smith. June 2007.
Doherty JA, Cushing-Haugen KL, Saltzman BS, et al. 2007. Long-term use 
of post-menopausal estrogen and progestin hormone therapies and the 
risk of endometrial cancer. Am J Obstet Gynecol, 197:139e1–e7.
Ehara S, Ueda M, Naruko T, et al. 2001. Elevated levels of oxidized low 
density lipoprotein show a positive relationship with the severity of 
acute coronary syndromes. Circulation, 103:1955–160.
Elestrin® PI. 2007. Elestrin® prescribing information. Fairﬁ  eld, New Jersey, 
USA: Kenwood Therapeutics. January 2007.
Erianne JA, Winter L, Jr. 1997. Comparison of local tolerability and 
adhesion of a new matrix system (Menorest®) for estradiol delivery 
with an established transdermal membrane system (Estraderm TTS®). 
Maturitas, 26:95–101.
Estraderm® PI. 2005. Estraderm® prescribing information. Hanover, NJ, 
USA: Novartis. January 2005.
Evamist™ PI. 2008. Evamist™ prescribing information. St. Louis, MO, 
USA: Ther-Rx Corporation. January 2008.
Fletcher B, Berra K, Ades P, et al. 2005. AHA Scientiﬁ  c Statement: 
Managing Abnormal Blood Lipids. A collaborative approach. 
Circulation, 112:3184–209.
Fugate SE, Church CO. 2004. Nonestrogen treatment modalities for 
vasomotor symptoms associated with menopause. Ann Pharmacother, 
38:1482–99.
Gleason CE, Carlsson CM, Johnson S, et al. 2005. Clinical pharmacology 
and differential cognitive efﬁ  cacy of estrogen preparation. Ann NY 
Acad Sci, 1052:93–115.
Gomes MPV, Deitcher SR. 2004. Risk of venous thromboembolic disease 
associated with hormonal contraceptives and hormone replacement 
therapy: a clinical review. Arch Intern Med, 164:1965–76.
Grady D, Gebretsadik T, Kerlikowske K, et al. 1995. Hormone replacement 
therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol, 
85:304–13.
Grady D, Herrington D, Bittner V, et al. 2002. Cardiovascular disease 
outcomes during 6.8 years of hormone therapy. Heart and estro-
gen/progestin replacement study follow-up (HERS II). JAMA, 
288:49–57.
Grodstein F, Stampfer MJ, Manson JE, et al. 1996. Post-menopausal 
estrogen and progestin use and the risk of cardiovascular disease. 
N Engl J Med, 335:453–61.
Hanggi W, Lippuner K, Riesen W, et al. 1997. Long term inﬂ  uence of dif-
ferent post-menopausal hormone replacement therapy on lipoprotein: 
A randomized study. Br J Obstet Gynaecol, 104:708–17.
Harman SM, Brinton EA, Cedars M, et al. 2005. KEEPS: The Kronos Early 
Estrogen Prevention Study. Climacteric, 8:3–12.
Henderson BE, Paganini-Hill A, Ross RK. 1988. Estrogen replacement 
therapy and protection from acute myocardial infarction. Am J Obstest 
Gynecol, 159:312–7.
Hersh AL, Stefanick ML, Stafford RS. 2004. National use of post-
menopausal hormone therapy. Annual trends and response to recent 
evidence. JAMA, 291:47–53.
Hing E, Brett KM. 2003. Changes in US prescribing patterns of menopausal 
hormone therapy, 2001–2003. Obstet Gynecol, 108:33–40.
Hivonen E, Lamberg-Allardt C, Lankinen KS, Geurts P, Wilen-
Rosenqvist G. 1997. Transdermal oestradiol gel in the treatment of the 
climacterium: a comparison with oral therapy. Br J Obstet Gynaecol, 
104(Suppl 16):19–25.
Hope S, Rees MCP. 1995. Why do British women start and stop hormone 
therapy? J Br Menopause Soc, 1:26–7.
Hylley S, Grady D, Bush T, et al. 1998. Randomized trial of estrogen plus 
progestin for secondary prevention of coronary heart disease in post-
menopausal women. JAMA, 280:605–13.
Humphrey LL, Chan BD, Sox HC. 2002. Post-menopausal hormone replace-
ment therapy and the primary prevention of cardiovascular disease. Ann 
Intern Med, 137:273–84.
Kayser J, Ettinger, B, Pressman A. 2001. Postmenspausal hormone 
support: discontinuation of raloxifene versus estrogen. Menopause, 
8:328–32.
Kisilevsky R, Subrahmanyan L. 1992. Serum amyloid A changes high 
density lipoprotein’s cellular afﬁ  nity: a clue to serum amyloid A’s 
principal function. Lab Invest, 66:778–85.
Lacut K, Oger E, Le Gal G, et al. 2003. Differential effects of oral and trans-
dermal postmenopausal estrogen replacement therapies on C-reactive 
protein. Thromb Haemost, 90:124–31.
Liang JS, Schreiber BM, Salmona M, et al. 1996. Amino terminal region of 
acute phase, but not constitutive, serum amyloid A (apoSAA) speciﬁ  -
cally binds and transports cholesterol into aortic smooth muscle and 
HepG2 cells. J Lipid Res, 37:2109–16.
Lobo RA. 2004. The rationale for low-dose hormonal therapy. Endocrine, 
24:217–21.
Mattsson LA, Bohnet HG, Gredmark T, et al. 1999. Continuous, combined 
hormone replacement: a randomized comparison of transdermal and 
oral preparations. Obstet Gynecol, 94:61–5.
McNamara JR, Jenner JL, Li A, et al. 1992. change in LDL particle size is 
associated with changes in plasma triglyceride concentration. Arterio-
scler Thromb, 12:1284–90.
Menon DV, Vongpatanasin W. 2006. Effects of transdermal estrogen 
replacement therapy on cardiovascular risk factors. Treat Endocrinol, 
5:37–51.
Minkin MJ. 2002. Considerations in the choice of oral vs transdermal 
hormone therapy: A review. J Reprod Med, 49:311–20.
Musel AL, Warshaw EM. 2006. Cutaneous reactions to transdermal thera-
peutic systems. Dermatitis 17:109–22.
Nachtigall LE. 1995. Emerging delivery systems for estrogen replace-
ment: Aspects of transdermal and oral delivery. Am J Obstet Gynecol, 
173:993–7.
Nahas EAP, Nahas-Neto J, Orsatti FL, et al. 2007. Efﬁ  cacy and safety 
of a soy isoﬂ  avone extract in post-menopausal women: A ran-
domized, double-blind, and placebo-controlled study. Maturitas, 
58:249–58.
Nelson HD, Humphrey LL, LeBlanc E, et al. 2005. Hormone therapy for 
the prevention of chronic conditions in post-menopausal women: 
recommendations from the US Preventive Services Task Force. Ann 
Intern Med, 142:855–60.
Newton KM, Reed SD, LaCroix AZ, et al. 2006. Treatment of vasomotor 
symptoms of menopause with black cohosh, multibotanicals, soy, 
hormone therapy, or placebo. Ann Intern Med, 145:869–79.
Oger E, Alhenc-Gelas M, Lacut K, et al. 2003. Differential effects of oral 
and transdermal estrogen/progesterone regimens on sensitivity to acti-
vated protein C among post-menopausal women. A randomized trial. 
Arterioscler Thromb Vasc Biol, 23:1671–76.
Post MS, Christella M, Thomassen LGD, et al. 2003. Effect of oral and 
transdermal estrogen replacement therapy on hemostatic variables 
associated with venous thrombosis: A randomized, placebo-controlled 
study in post-menopausal women. Arterioscler Thromb Vasc Biol, 
23:1116–21.
Pradhan AD; Manson JE; RossouwJE, et al. 2002. Inﬂ  ammatory biomarkers, 
hormone replacement therapy, and incident of coronary heart disease: 
prospective analysis from the Women’s Health Initiative observational 
study. JAMA, 288:980–7.
Rapkin AJ. 2007. Vasomotor symptoms in menopause: physiologic 
condition and central nervous system approaches to treatment. Am J 
Obstet Gynecol, 196:97–106.
Reginster JY, Donazzolo Y, Brion N, Lins R. 2000. Estradiol pharmacokinetics 
after transdermal application of patches to post-menopausal women: 
matrix versus reservoir patches. Climacteric, 3:168–75.Drug Design, Development and Therapy 2008:2 202
Kopper et al
Ridker PM, Cushman M, Stampfer MJ, et al. 2000. C-reactive protein 
and other markers of inﬂ  ammation in the prediction of cardiovascular 
disease in women. N Engl J Med, 342:836–43.
Rodeghiero F, Tosetto A. 1999. Activated protein C resistance and factor 
V Leiden are independent risk factors for venous thromboembolism. 
Ann Intern Med, 130:643–50.
Rossouw JE, Anderson GL, Prentice RL, et al. 2002. Writing group for 
the Women’s Health Initiative Investigators. Risks and beneﬁ  ts of 
estrogen plus progestin in healthy post-menopausal women: principal 
results from the Women’s Health Initiative randomized controlled trial. 
JAMA, 288:321–33.
Rossouw JE, Prentice RL, Manson JE, et al. 2007. Post-menopausal hor-
mone therapy and risk of cardiovascular disease by age and years since 
menopause. JAMA, 297:1465–77.
Sacks F, Walsh B. 1994. Sex hormones and lipoprotein metabolism. Curr 
Opin Lipidol, 5:236–40.
Samsioe G. 2004. Transdermal hormone therapy: gels and patches. Cli-
macteric, 7:347–56.
Sattar N, Perera M, Small M, et al. 1999. Hormone replacement therapy 
and sensitive C-reactive protein concentrations in women with type-2 
diabetes. Lancet, 354:487–8.
Scarabin PY, Oger E, Plu-Bureau G, et al. 2003. Differential associatin 
of oral and transdermal oestrogen-replacement therapy with venous 
thromboembolism risk. Lancet, 362:428–32.
Schmidt JW, Wollner D, Curcio J, et al. 2006. Hormone replacement 
therapy in menopausal women: Past problems and future possibilities. 
Gynecological Endocrinology, 22:564–77.
Scott RT, Jr, Ross B, Anderson C, et al. 1991. Pharmacokinetics of per-
cutaneous estradiol: a crossover study using a gel and a transdermal 
system in comparison with oral micronized estradiol. Obstet Gynecol, 
77:758–64.
Shulman LP, Yankov V, Uhl K. 2003. Safety and efﬁ  cacy of a continuous 
once-a-week 17β-estradiol/levonorgestrel transdermal system and 
its effects on vasomotor symptoms and endometrial safety in post-
menopausal women: The results of two multicenter, double-blind, 
randomized, controlled trials. Menopause, 9:195–207.
Simon JA, Bouchard C, Waldebaum A, et al. 2007. Low dose of transdermal 
estradiol gel for treatment of symptomatic post-menopausal women: a 
randomized controlled trial. Obstet Gynecol, 109:588–96.
Simon JA, Ravnikar V. 2007. Transdermal estrogen therapy: evidence and 
update. The Female Patient, November Supplement.
Simon JA. 2004. New options in transdermal administration. OBG Manage-
ment, November Supplement, 16–9.
Simon JA, Estrasorb Study Group. 2006. Estradiol in micellar nanoparticles: 
the efﬁ  cacy and safety of a novel transdermal drug-delivery technol-
ogy in the management of moderate to severe vasomotor symptoms. 
Menopause, 13:222–31.
Skouby SO, Gram J, Anderson LF, et al. 2002. Hormone replacement 
therapy: estrogen and progestin effects on plasma C-reactive protein 
concentrations. Am J Obstet Gynecol, 186:969–77.
Smith SC, Jr, Anderson JL, Cannon RO 3rd, et al. 2004. CDC/AHA 
Workshop on markers of inﬂ  ammation and cardiovascular disease: 
Application to clinical and public health practice: report from the clinical 
practice discussion group. Circulation, 110:e550–3.
Soules MR, Sherman S, Parrott E, et al. 2001. Executive summary: stages 
of reproductive aging workshop (STRAW). Menopause, 8:402–7.
Speroff L, the United States VR Investigator Group. 2003. Efﬁ  cacy and 
tolerability of a novel estradiol vaginal ring for relief of menopausal 
symptoms. Obstet Gynecol, 102:823–34.
Stampfer MJ, Colditz GA, Willett WC, et al. 1991. Post-menopausal estro-
gen therapy and cardiovascular disease: ten year follow-up from the 
nurses’ health study. N Engl J Med, 325:756–62.
Stampfer MJ, Willett WC, Colditz GA, et al. 1985. A prospective study of 
post-menopausal estrogen therapy and coronary heart disease. N Engl 
J Med, 313:1044–9.
Stephenson J. 2003. FDA orders estrogen safety warnings: agency offers 
guidance for HRT use. JAMA, 289:537–8.
Straczek C, Oger E, Yon de Jonage-canonico MB, et al. 2005. Prothrombotic 
mutations, hormone therapy and venous thromboembolism among 
post-menopausal women. Circulation, 112:3495–500.
Strandberg TE, Olavi Ylikorkala O, Tikkanen MJ. 2003. Differing effects 
of oral and transdermal hormone replacement therapy on cardiovas-
cular risk factors in healthy postmenopausal women. Am J Cardiol, 
92:212–4.
Stumpf PG. 1990. Pharmacokinetics of estrogen. Obstet Gyneco, 
75(Suppl):9s–17s.
Sturdee D, Archer D, Rakov V, et al. 2008. Ultra-low-dose continuous 
combined estradiol and norethisterone acetate: improved bleeding 
proﬁ  le in post-menopausal women. Climacteric, 11:63–73.
Sturdee DW, Archer DF, Rakov V, et al. 2008. Ultra-low-dose continuous 
combined estradiol and norethisterone acetate: improved bleeding 
proﬁ  le in post-menopausal women. Climacteric, 11:68–73.
The North American Menopause Society. 2007. Estrogen and progesto-
gen use in peri- and post-menopausal women: March 2007 position 
statement of the North American Menopause Society. Menopause, 
14:168–82.
[NAMS] The North American Menopause Society. 2003. Role of progesto-
gen in hormone therapy for post-menopausal women: position statement 
of The North American Menopause Society. Menopause,10:113–32.
Van Baal W M, Kenemans P, van der Mooren MJ, et al. 1999. Increased C-
reactive protein levels during short-term hormone replacement therapy 
in healthy postmenopausal women. Thromb Haemost, 81:925–8.
Vehkavaara S, Hakala-Ala-Pietilä T, Virkamäki A, et al. 2000. Differ-
ential effects of oral and transdermal estrogen replacement therapy 
on endothelial function in post-menopausal women. Circulation, 
102:2687–93.
Vongpatanasin W, Tuncel M, Wang Z, et al. 2003. Differential effects of oral 
versus transdermal estrogen replacement therapy on C-reactive protein 
in postmenopausal women. J Am Coll Cardiol, 41:1358–63.
Wakatsuki A, Okatani Y, Ikenoue N, et al. 2002. Different effects of oral 
conjugated equine estrogen and transdermal estrogen replacement 
therapy on size and oxidative susceptibility of low-density lipoprotein 
particles in post-menopausal women. Circulation, 106:1771–6.
Weissberger AJ, HO KKY, Lazarus L. 1991. Contrasting effects of oral 
and transdermal routes of estrogen replacement therapy on 24-hour 
growth hormone (GH) secretion, insulin-like growth factor I, and 
GH-binding protein in post-menopausal women. J Clin Endocrinol 
Metab, 72:374–81.